The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Published Online:https://doi.org/10.1176/ajp.126.9.1315

The authors present case reports of three patients with similar pathology in their social, vocational, and sexual adjustment who developed paranoid or paranoid hallucinatory syndromes in conjunction with the abuse of mephentermine from Wyamine inhalers. Their symptomatology appeared clinically identical to amphetamine psychosis or acute paranoid schizophrenia. The authors conclude that, if abused, the Wyamine inhaler is potentially dangerous and that its availability on the market constitutes a loophole in the current regulations governing stimulant drugs.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.